News | May 05, 2022
JBCPL emerges as the fastest growing pharma company: Report
Ranked 25th with an impressive growth rate of 29% among Indian pharma companies in FY 2021-22
Ranked 25th with an impressive growth rate of 29% among Indian pharma companies in FY 2021-22
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
Price was the key driver for the period
The partnership is already underway having launched earlier last week, and the contract could be worth up to £211 million.
Key takeaways of Q3FY22 quarter & conference call highlights
_256_384.jpg)
Ind-Ra expects IPM revenue growth of over 12% yoy for FY22.
Ind-Ra continues to expect IPM’s revenue to grow over 12% yoy in FY22
Acute therapies continue to report strong growth compared to chronic ones.
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
Subscribe To Our Newsletter & Stay Updated
